Innovent Announces Clinical Data of Multiple Trials Will be

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Related Keywords

China , Taiwan , Japan , Huazhong , Hubei , United States , Shanghai , Hong Kong , Long Wu , Ding Ma , Jiangsu , Jian Zhou , Zhejiang , Zhongshan , Anhui , Suzhou , Shen Lin , Henan , Guangdong , Jilin , Peking , Beijing , Macau , Qing Zhou , Chinese , American , Innovent Biologics , Xiaoyong Huang , Eli Lilly , Tongji Hopstial , Qinglei Gao , Adimab Incyte , Incyte Pemazyre , Guo Ming Shi , Jianming Xu , University Cancer Hospital , Md Anderson Cancer Center , Guangdong Lung Cancer Institute , Incyte Corporation , Huazhong University Of Science , Prnewswire Innovent Biologics Inc , Drug Administration , People Liberation Army , Hong Kong Department Of Health , National Reimbursement Drug List , American Association For Cancer Research , Fudan University , National Medical Products Administration , Tongji Medical College , American Association , Cancer Research , Annual Meeting , Guangdong Provincial People , Monday Apr , Peking University Cancer Hospital , Fifth Medical Center , Liberation Army General , Huazhong University , Zhongshan Hospital , Mainland China , Taiwan Food , Hong Kong Department , Genfleet Therapeutics , Main Board , Stock Exchange , Hong Kong Limited , Cancer Center ,